A BILL 
To expand research on cannabidiol and marijuana, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Medical Marijuana and Cannabidiol Research Expansion 
5
Act’’. 
6
(b) TABLE OF CONTENTS.—The table of contents for 
7
this Act is as follows: 
8
21:54 Jul 21, 2022
H8454
2 
•HR 8454 IH
Sec. 1. Short title; table of contents. 
Sec. 2. Definitions. 
TITLE I—REGISTRATIONS FOR MARIJUANA RESEARCH 
Sec. 101. Marijuana research applications. 
Sec. 102. Research protocols. 
Sec. 103. Applications to manufacture marijuana for research. 
Sec. 104. Adequate and uninterrupted supply. 
Sec. 105. Security requirements. 
Sec. 106. Prohibition against reinstating interdisciplinary review process for 
non-NIH-funded researchers. 
TITLE II—DEVELOPMENT OF FDA-APPROVED DRUGS USING 
CANNABIDIOL AND MARIJUANA 
Sec. 201. Medical research on cannabidiol. 
Sec. 202. Registration for the commercial production and distribution of Food 
and Drug Administration-approved drugs. 
TITLE III—DOCTOR-PATIENT RELATIONSHIP 
Sec. 301. Doctor-patient relationship. 
TITLE IV—FEDERAL RESEARCH 
Sec. 401. Federal research. 
SEC. 2. DEFINITIONS. 
1
(a) IN GENERAL.—In this Act— 
2
(1) the term ‘‘appropriately registered’’ means 
3
that an individual or entity is registered under the 
4
Controlled Substances Act (21 U.S.C. 801 et seq.) 
5
to engage in the type of activity that is carried out 
6
by the individual or entity with respect to a con-
7
trolled substance on the schedule that is applicable 
8
to cannabidiol or marijuana, as applicable; 
9
(2) the term ‘‘cannabidiol’’ means— 
10
(A) the substance, cannabidiol, as derived 
11
from 
marijuana 
that 
has 
a 
delta-9- 
12
tetrahydrocannabinol level that is greater than 
13
0.3 percent; and 
14
21:54 Jul 21, 2022
H8454
3 
•HR 8454 IH
(B) the synthetic equivalent of the sub-
1
stance described in subparagraph (A); 
2
(3) the terms ‘‘controlled substance’’, ‘‘dis-
3
pense’’, ‘‘distribute’’, ‘‘manufacture’’, ‘‘marijuana’’, 
4
and ‘‘practitioner’’ have the meanings given such 
5
terms in section 102 of the Controlled Substances 
6
Act (21 U.S.C. 802), as amended by this Act; 
7
(4) the term ‘‘covered institution of higher edu-
8
cation’’ means an institution of higher education (as 
9
defined in section 101 of the Higher Education Act 
10
of 1965 (20 U.S.C. 1001)) that— 
11
(A)(i) has highest or higher research activ-
12
ity, as defined by the Carnegie Classification of 
13
Institutions of Higher Education; or 
14
(ii) is an accredited medical school or an 
15
accredited school of osteopathic medicine; and 
16
(B) is appropriately registered under the 
17
Controlled Substances Act (21 U.S.C. 801 et 
18
seq.); 
19
(5) the term ‘‘drug’’ has the meaning given the 
20
term in section 201(g)(1) of the Federal Food, 
21
Drug, and Cosmetic Act (21 U.S.C. 321(g)(1)); 
22
(6) the term ‘‘medical research for drug devel-
23
opment’’ means medical research that is— 
24
21:54 Jul 21, 2022
H8454
4 
•HR 8454 IH
(A) a preclinical study or clinical investiga-
1
tion conducted in accordance with section 
2
505(i) of the Federal Food, Drug, and Cos-
3
metic Act (21 U.S.C. 355(i)) or otherwise per-
4
mitted by the Department of Health and 
5
Human Services to determine the potential 
6
medical benefits of marijuana or cannabidiol as 
7
a drug; and 
8
(B) conducted by a covered institution of 
9
higher education, practitioner, or manufacturer 
10
that is appropriately registered under the Con-
11
trolled Substances Act (21 U.S.C. 801 et seq.); 
12
and 
13
(7) the term ‘‘State’’ means any State of the 
14
United States, the District of Columbia, and any 
15
territory of the United States. 
16
(b) UPDATING TERM.—Section 102(16) of the Con-
17
trolled Substances Act (21 U.S.C. 802(16)) is amended— 
18
(1) in subparagraph (A), by striking ‘‘the term 
19
‘marihuana’ means’’ and inserting ‘‘the terms ‘mari-
20
huana’ and ‘marijuana’ mean’’; and 
21
(2) in subparagraph (B), by striking ‘‘The term 
22
‘marihuana’ does not’’ and inserting ‘‘The terms 
23
‘marihuana’ and ‘marijuana’ do not’’. 
24
21:54 Jul 21, 2022
H8454
5 
•HR 8454 IH
TITLE I—REGISTRATIONS FOR 
1
MARIJUANA RESEARCH 
2
SEC. 101. MARIJUANA RESEARCH APPLICATIONS. 
3
Section 303(f) of the Controlled Substances Act (21 
4
U.S.C. 823(f)) is amended— 
5
(1) by redesignating paragraphs (1) through 
6
(5) as subparagraphs (A) through (E), respectively; 
7
(2) by striking ‘‘(f) The Attorney General’’ and 
8
inserting ‘‘(f)(1) The Attorney General’’; 
9
(3) by striking ‘‘Registration applications’’ and 
10
inserting the following: 
11
‘‘(2)(A) Registration applications’’; 
12
(4) by striking ‘‘Article 7’’ and inserting the 
13
following: 
14
‘‘(3) Article 7’’; and 
15
(5) by inserting after paragraph (2)(A), as so 
16
designated, the following: 
17
‘‘(B)(i) The Attorney General shall register a practi-
18
tioner to conduct research with marijuana (including any 
19
derivative, extract, preparation, and compound thereof) 
20
if— 
21
‘‘(I) the applicant’s research protocol— 
22
‘‘(aa) has been reviewed and allowed— 
23
‘‘(AA) by the Secretary of Health and 
24
Human Services under section 505(i) of 
25
21:54 Jul 21, 2022
H8454
6 
•HR 8454 IH
the Federal Food, Drug, and Cosmetic Act 
1
(21 U.S.C. 355(i)); 
2
‘‘(BB) by the National Institutes of 
3
Health or another Federal agency that 
4
funds scientific research; or 
5
‘‘(CC) pursuant to sections 1301.18 
6
and 1301.32 of title 21, Code of Federal 
7
Regulations, or any successors thereto; and 
8
‘‘(II) the applicant has demonstrated to the At-
9
torney General that there are effective procedures in 
10
place to adequately safeguard against diversion of 
11
the controlled substance for legitimate medical or 
12
scientific use pursuant to section 105 of the Medical 
13
Marijuana and Cannabidiol Research Expansion Act, 
14
including demonstrating that the security measures 
15
are adequate for storing the quantity of marijuana 
16
the applicant would be authorized to possess. 
17
‘‘(ii) The Attorney General may deny an application 
18
for registration under this subparagraph only if the Attor-
19
ney General determines that the issuance of the registra-
20
tion would be inconsistent with the public interest. In de-
21
termining the public interest, the Attorney General shall 
22
consider the factors listed in— 
23
‘‘(I) subparagraphs (B) through (E) of para-
24
graph (1); and 
25
21:54 Jul 21, 2022
H8454
7 
•HR 8454 IH
‘‘(II) subparagraph (A) of paragraph (1), if the 
1
applicable State requires practitioners conducting re-
2
search to register with a board or authority de-
3
scribed in such subparagraph (A). 
4
‘‘(iii)(I) Not later than 60 days after the date on 
5
which the Attorney General receives a complete applica-
6
tion for registration under this subparagraph, the Attor-
7
ney General shall— 
8
‘‘(aa) approve the application; or 
9
‘‘(bb) request supplemental information. 
10
‘‘(II) For purposes of subclause (I), an application 
11
shall be deemed complete when the applicant has sub-
12
mitted documentation showing that the requirements 
13
under clause (i) are satisfied. 
14
‘‘(iv) Not later than 30 days after the date on which 
15
the Attorney General receives supplemental information as 
16
described in clause (iii)(I)(bb) in connection with an appli-
17
cation described in this subparagraph, the Attorney Gen-
18
eral shall approve or deny the application. 
19
‘‘(v) If an application described in this subparagraph 
20
is denied, the Attorney General shall provide a written ex-
21
planation of the basis of denial to the applicant.’’. 
22
SEC. 102. RESEARCH PROTOCOLS. 
23
(a) IN GENERAL.—Paragraph (2)(B) of section 
24
303(f) of the Controlled Substances Act (21 U.S.C. 
25
21:54 Jul 21, 2022
H8454
8 
•HR 8454 IH
823(f)), as added by section 101 of this Act, is further 
1
amended by adding at the end the following: 
2
‘‘(vi)(I) If the Attorney General grants an application 
3
for registration under clause (i), the registrant may amend 
4
or supplement the research protocol without notification 
5
to, or review by, the Drug Enforcement Administration 
6
if the registrant does not change— 
7
‘‘(aa) the quantity or type of marijuana or 
8
cannabidiol (including any derivative, extract, prepa-
9
ration, and compound thereof); 
10
‘‘(bb) the source of such marijuana or 
11
cannabidiol; or 
12
‘‘(cc) the conditions under which such mari-
13
juana or cannabidiol is stored, tracked, or adminis-
14
tered. 
15
‘‘(II)(aa) If a registrant under clause (i) seeks to 
16
change the type of marijuana or cannabidiol (including 
17
any derivative, extract, preparation, and compound there-
18
of), the source of such marijuana or cannabidiol, or the 
19
conditions under which such marijuana or cannabidiol is 
20
stored, tracked, or administered, the registrant shall notify 
21
the Attorney General via registered mail, or an electronic 
22
means permitted by the Attorney General, not later than 
23
30 days before implementing an amended or supplemental 
24
research protocol. 
25
21:54 Jul 21, 2022
H8454
9 
•HR 8454 IH
‘‘(bb) A registrant may proceed with an amended or 
1
supplemental research protocol described in item (aa) if 
2
the Attorney General does not explicitly object during the 
3
30-day period beginning on the date on which the Attorney 
4
General receives the notice under item (aa). 
5
‘‘(cc) The Attorney General may only object to an 
6
amended or supplemental research protocol under this 
7
subclause if additional security measures are needed to 
8
safeguard against diversion or abuse. 
9
‘‘(dd) If a registrant under clause (i) seeks to address 
10
additional security measures identified by the Attorney 
11
General under item (cc), the registrant shall notify the At-
12
torney General via registered mail, or an electronic means 
13
permitted by the Attorney General, not later than 30 days 
14
before implementing an amended or supplemental research 
15
protocol. 
16
‘‘(ee) A registrant may proceed with an amended or 
17
supplemental research protocol described in item (dd) if 
18
the Attorney General does not explicitly object during the 
19
30-day period beginning on the date on which the Attorney 
20
General receives the notice under item (dd). 
21
‘‘(III)(aa) If a registrant under clause (i) seeks to 
22
change the quantity of marijuana needed for research and 
23
the change in quantity does not impact the factors de-
24
scribed in item (bb) or (cc) of subclause (I) of this clause, 
25
21:54 Jul 21, 2022
H8454
10 
•HR 8454 IH
the registrant shall notify the Attorney General via reg-
1
istered mail or using an electronic means permitted by the 
2
Attorney General. 
3
‘‘(bb) A notification under item (aa) shall include— 
4
‘‘(AA) the Drug Enforcement Administration 
5
registration number of the registrant; 
6
‘‘(BB) the quantity of marijuana or cannabidiol 
7
already obtained; 
8
‘‘(CC) the quantity of additional marijuana or 
9
cannabidiol needed to complete the research; and 
10
‘‘(DD) an attestation that the change in quan-
11
tity does not impact the source of the marijuana or 
12
cannabidiol or the conditions under which the mari-
13
juana or cannabidiol is stored, tracked, or adminis-
14
tered. 
15
‘‘(cc) The Attorney General shall ensure that— 
16
‘‘(AA) any registered mail return receipt with 
17
respect to a notification under item (aa) is sub-
18
mitted for delivery to the registrant providing the 
19
notification not later than 3 days after receipt of the 
20
notification by the Attorney General; and 
21
‘‘(BB) notice of receipt of a notification using 
22
an electronic means permitted under item (aa) is 
23
provided to the registrant providing the notification 
24
21:54 Jul 21, 2022
H8454
11 
•HR 8454 IH
not later than 3 days after receipt of the notification 
1
by the Attorney General. 
2
‘‘(dd)(AA) On and after the date described in subitem 
3
(BB), a registrant that submits a notification in accord-
4
ance with item (aa) may proceed with the research as if 
5
the change in quantity has been approved on such date, 
6
unless the Attorney General notifies the registrant of an 
7
objection described in item (ee). 
8
‘‘(BB) The date described in this subitem is the date 
9
on which a registrant submitting a notification under item 
10
(aa) receives the registered mail return receipt with re-
11
spect to the notification or the date on which the reg-
12
istrant receives notice that the notification using an elec-
13
tronic means permitted under item (aa) was received by 
14
the Attorney General, as the case may be. 
15
‘‘(ee) A notification submitted under item (aa) shall 
16
be deemed to be approved unless the Attorney General, 
17
not later than 10 days after receiving the notification, ex-
18
plicitly objects based on a finding that the change in quan-
19
tity— 
20
‘‘(AA) does impact the source of the marijuana 
21
or cannabidiol or the conditions under which the 
22
marijuana or cannabidiol is stored, tracked, or ad-
23
ministered; or 
24
21:54 Jul 21, 2022
H8454
12 
•HR 8454 IH
‘‘(BB) necessitates that the registrant imple-
1
ment additional security measures to safeguard 
2
against diversion or abuse. 
3
‘‘(IV) Nothing in this clause shall limit the authority 
4
of the Secretary of Health and Human Services over re-
5
quirements related to research protocols, including 
6
changes in— 
7
‘‘(aa) the method of administration of mari-
8
juana or cannabidiol; 
9
‘‘(bb) the dosing of marijuana or cannabidiol; 
10
and 
11
‘‘(cc) the number of individuals or patients in-
12
volved in research.’’. 
13
(b) REGULATIONS.—Not later than 1 year after the 
14
date of enactment of this Act, the Attorney General shall 
15
promulgate regulations to carry out the amendment made 
16
by this section. 
17
SEC. 103. APPLICATIONS TO MANUFACTURE MARIJUANA 
18
FOR RESEARCH. 
19
(a) IN GENERAL.—Section 303 of the Controlled 
20
Substances Act (21 U.S.C. 823), as amended by sections 
21
101 and 102 of this Act, is further amended— 
22
(1) by redesignating subsections (c) through (k) 
23
as subsections (d) through (l), respectively; 
24
21:54 Jul 21, 2022
H8454
13 
•HR 8454 IH
(2) by inserting after subsection (b) the fol-
1
lowing: 
2
‘‘(c)(1)(A) As it relates to applications to manufac-
3
ture marijuana for research purposes, when the Attorney 
4
General places a notice in the Federal Register to increase 
5
the number of entities registered under this Act to manu-
6
facture marijuana to supply appropriately registered re-
7
searchers in the United States, the Attorney General shall, 
8
not later than 60 days after the date on which the Attor-
9
ney General receives a completed application— 
10
‘‘(i) approve the application; or 
11
‘‘(ii) request supplemental information. 
12
‘‘(B) For purposes of subparagraph (A), an applica-
13
tion shall be deemed complete when the applicant has sub-
14
mitted documentation showing each of the following: 
15
‘‘(i) The requirements designated in the notice 
16
in the Federal Register are satisfied. 
17
‘‘(ii) The requirements under this Act are satis-
18
fied. 
19
‘‘(iii) The applicant will limit the transfer and 
20
sale of any marijuana manufactured under this sub-
21
section— 
22
‘‘(I) to researchers who are registered 
23
under this Act to conduct research with con-
24
trolled substances in schedule I; and 
25
21:54 Jul 21, 2022
H8454
14 
•HR 8454 IH
‘‘(II) for purposes of use in preclinical re-
1
search or in a clinical investigation pursuant to 
2
an investigational new drug exemption under 
3
505(i) of the Federal Food, Drug, and Cos-
4
metic Act (21 U.S.C. 355(i)). 
5
‘‘(iv) The applicant will transfer or sell any 
6
marijuana manufactured under this subsection only 
7
with prior, written consent for the transfer or sale 
8
by the Attorney General. 
9
‘‘(v) The applicant has completed the applica-
10
tion and review process under subsection (a) for the 
11
bulk manufacture of controlled substances in sched-
12
ule I. 
13
‘‘(vi) The applicant has established and begun 
14
operation of a process for storage and handling of 
15
controlled substances in schedule I, including for in-
16
ventory control and monitoring security in accord-
17
ance with section 105 of the Medical Marijuana and 
18
Cannabidiol Research Expansion Act. 
19
‘‘(vii) The applicant is licensed by each State in 
20
which the applicant will conduct operations under 
21
this subsection, to manufacture marijuana, if that 
22
State requires such a license. 
23
‘‘(C) Not later than 30 days after the date on which 
24
the Attorney General receives supplemental information 
25
21:54 Jul 21, 2022
H8454
15 
•HR 8454 IH
requested under subparagraph (A)(ii) with respect to an 
1
application, the Attorney General shall approve or deny 
2
the application. 
3
‘‘(2) If an application described in this subsection is 
4
denied, the Attorney General shall provide a written expla-
5
nation of the basis of denial to the applicant.’’; 
6
(3) in subsection (h)(2), as so redesignated, by 
7
striking ‘‘subsection (f)’’ each place it appears and 
8
inserting ‘‘subsection (g)’’; 
9
(4) in subsection (j)(1), as so redesignated, by 
10
striking ‘‘subsection (d)’’ and inserting ‘‘subsection 
11
(e)’’; and 
12
(5) in subsection (k), as so redesignated, by 
13
striking ‘‘subsection (f)’’ each place it appears and 
14
inserting ‘‘subsection (g)’’. 
15
(b) TECHNICAL AND CONFORMING AMENDMENTS.— 
16
(1) The Controlled Substances Act (21 U.S.C. 
17
801 et seq.) is amended— 
18
(A) in section 102 (21 U.S.C. 802)— 
19
(i) in paragraph (52)(B)— 
20
(I) by striking ‘‘303(f)’’ each 
21
place 
it 
appears 
and 
inserting 
22
‘‘303(g)’’; and 
23
21:54 Jul 21, 2022
H8454
16 
•HR 8454 IH
(II) in clause (i), by striking 
1
‘‘(d), or (e)’’ and inserting ‘‘(e), or 
2
(f)’’; and 
3
(ii) in paragraph (54), by striking 
4
‘‘303(f)’’ each place it appears and insert-
5
ing ‘‘303(g)’’; 
6
(B) in section 302(g)(5)(A)(iii)(I)(bb) (21 
7
U.S.C. 822(g)(5)(A)(iii)(I)(bb)), by striking 
8
‘‘303(f)’’ and inserting ‘‘303(g)’’; 
9
(C) in section 304 (21 U.S.C. 824), by 
10
striking ‘‘303(g)(1)’’ each place it appears and 
11
inserting ‘‘303(h)(1)’’; 
12
(D) in section 307(d)(2) (21 U.S.C. 
13
827(d)(2)), by striking ‘‘303(f)’’ and inserting 
14
‘‘303(g)’’; 
15
(E) in section 309A(a)(2) (21 U.S.C. 
16
829a(a)(2)), in the matter preceding subpara-
17
graph (A), by striking ‘‘303(g)(2)’’ and insert-
18
ing ‘‘303(h)(2)’’; 
19
(F) in section 311(h) (21 U.S.C. 831(h)), 
20
by striking ‘‘303(f)’’ each place it appears and 
21
inserting ‘‘303(g)’’; 
22
(G) in section 401(h)(2) (21 U.S.C. 
23
841(h)(2)), by striking ‘‘303(f)’’ each place it 
24
appears and inserting ‘‘303(g)’’; 
25
21:54 Jul 21, 2022
H8454
17 
•HR 8454 IH
(H) in section 403(c)(2)(B) (21 U.S.C. 
1
843(c)(2)(B)), by striking ‘‘303(f)’’ and insert-
2
ing ‘‘303(g)’’; and 
3
(I) in section 512(c)(1) (21 U.S.C. 
4
882(c)(1)) by striking ‘‘303(f)’’ and inserting 
5
‘‘303(g)’’. 
6
(2) Section 1008(c) of the Controlled Sub-
7
stances Import and Export Act (21 U.S.C. 958(c)) 
8
is amended— 
9
(A) in paragraph (1), by striking ‘‘303(d)’’ 
10
and inserting ‘‘303(e)’’; and 
11
(B) in paragraph (2)(B), by striking 
12
‘‘303(h)’’ and inserting ‘‘303(i)’’. 
13
(3) Title V of the Public Health Service Act (42 
14
U.S.C. 290aa et seq.) is amended— 
15
(A) in section 520E–4(c) (42 U.S.C. 
16
290bb–36d(c)), by striking ‘‘303(g)(2)(B)’’ and 
17
inserting ‘‘303(h)(2)(B)’’; and 
18
(B) in section 544(a)(3) (42 U.S.C. 
19
290dd–3(a)(3)), by striking ‘‘303(g)’’ and in-
20
serting ‘‘303(h)’’. 
21
(4) Title XVIII of the Social Security Act (42 
22
U.S.C. 1395 et seq.) is amended— 
23
21:54 Jul 21, 2022
H8454
18 
•HR 8454 IH
(A) in section 1833(bb)(3)(B) (42 U.S.C. 
1
1395l(bb)(3)(B)), by striking ‘‘303(g)’’ and in-
2
serting ‘‘303(h)’’; 
3
(B) in section 1834(o)(3)(C)(ii) (42 U.S.C. 
4
1395m(o)(3)(C)(ii)), by striking ‘‘303(g)’’ and 
5
inserting ‘‘303(h)’’; and 
6
(C) in section 1866F(c)(3)(C) (42 U.S.C. 
7
1395cc–6(c)(3)(C)), by striking ‘‘303(g)’’ and 
8
inserting ‘‘303(h)’’. 
9
(5) Section 1903(aa)(2)(C)(ii) of the Social Se-
10
curity Act (42 U.S.C. 1396b(aa)(2)(C)(ii)) is 
11
amended by striking ‘‘303(g)’’ each place it appears 
12
and inserting ‘‘303(h)’’. 
13
SEC. 104. ADEQUATE AND UNINTERRUPTED SUPPLY. 
14
(a) IN GENERAL.—On an annual basis, the Attorney 
15
General, in consultation with the Secretary of Health and 
16
Human Services, shall assess whether there is an adequate 
17
and uninterrupted supply of marijuana, including of spe-
18
cific strains, for research purposes. 
19
(b) REPORT TO CONGRESS.—If the Attorney Gen-
20
eral, in consultation with the Secretary of Health and 
21
Human Services, determines there is an inadequate or in-
22
terrupted supply of marijuana, including of specific strains 
23
for research purposes, the Attorney General shall report 
24
21:54 Jul 21, 2022
H8454
19 
•HR 8454 IH
to Congress within 60 days of the determination on at 
1
least— 
2
(1) the factors contributing to the inadequate 
3
or interrupted supply of marijuana; 
4
(2) expected impacts of the inadequate or inter-
5
rupted supply on ongoing research protocols; and 
6
(3) specific steps the Attorney General will take 
7
to restore an adequate and uninterrupted supply of 
8
marijuana, including of specific strains, for research 
9
purposes. 
10
SEC. 105. SECURITY REQUIREMENTS. 
11
(a) IN GENERAL.—An individual or entity engaged 
12
in researching marijuana or its components shall store it 
13
in a securely locked, substantially constructed cabinet. 
14
(b) REQUIREMENTS FOR OTHER MEASURES.—Any 
15
other security measures required by the Attorney General 
16
to safeguard against diversion shall be consistent with 
17
those required for practitioners conducting research on 
18
other controlled substances in schedules I and II in section 
19
202(c) of the Controlled Substances Act (21 U.S.C. 
20
812(c)) that have a similar risk of diversion and abuse. 
21
21:54 Jul 21, 2022
H8454
20 
•HR 8454 IH
SEC. 106. PROHIBITION AGAINST REINSTATING INTER-
1
DISCIPLINARY REVIEW PROCESS FOR NON- 
2
NIH-FUNDED RESEARCHERS. 
3
The Secretary of Health and Human Services may 
4
not— 
5
(1) reinstate the Public Health Service inter-
6
disciplinary review process described in the guidance 
7
entitled ‘‘Guidance on Procedures for the Provision 
8
of Marijuana for Medical Research’’ (issued on May 
9
21, 1999); or 
10
(2) require another review of scientific protocols 
11
that is applicable only to research on marijuana or 
12
its components. 
13
TITLE 
II—DEVELOPMENT 
OF 
14
FDA-APPROVED 
DRUGS 
15
USING 
CANNABIDIOL 
AND 
16
MARIJUANA 
17
SEC. 201. MEDICAL RESEARCH ON CANNABIDIOL. 
18
Notwithstanding any provision of the Controlled Sub-
19
stances Act (21 U.S.C. 801 et seq.), the Safe and Drug- 
20
Free Schools and Communities Act (20 U.S.C. 7101 et 
21
seq.), chapter 81 of title 41, United States Code, or any 
22
other Federal law, an appropriately registered covered in-
23
stitution of higher education, practitioner, or manufac-
24
turer may manufacture, distribute, dispense, or possess 
25
marijuana or cannabidiol if the marijuana or cannabidiol 
26
21:54 Jul 21, 2022
H8454
21 
•HR 8454 IH
is manufactured, distributed, dispensed, or possessed, re-
1
spectively, for purposes of medical research for drug devel-
2
opment or subsequent commercial production in accord-
3
ance with section 202. 
4
SEC. 202. REGISTRATION FOR THE COMMERCIAL PRODUC-
5
TION AND DISTRIBUTION OF FOOD AND 
6
DRUG ADMINISTRATION-APPROVED DRUGS. 
7
The Attorney General shall register an applicant to 
8
manufacture or distribute cannabidiol or marijuana for 
9
the purpose of commercial production of a drug containing 
10
or derived from marijuana that is approved by the Sec-
11
retary of Health and Human Services under section 505 
12
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
13
355), in accordance with the applicable requirements 
14
under subsection (a) or (b) of section 303 of the Con-
15
trolled Substances Act (21 U.S.C. 823). 
16
TITLE III—DOCTOR-PATIENT 
17
RELATIONSHIP 
18
SEC. 301. DOCTOR-PATIENT RELATIONSHIP. 
19
It shall not be a violation of the Controlled Sub-
20
stances Act (21 U.S.C. 801 et seq.) for a State-licensed 
21
physician to discuss— 
22
(1) the currently known potential harms and 
23
benefits 
of 
marijuana 
derivatives, 
including 
24
cannabidiol, as a treatment with the legal guardian 
25
21:54 Jul 21, 2022
H8454
22 
•HR 8454 IH
of the patient of the physician if the patient is a 
1
child; or 
2
(2) the currently known potential harms and 
3
benefits of marijuana and marijuana derivatives, in-
4
cluding cannabidiol, as a treatment with the patient 
5
or the legal guardian of the patient of the physician 
6
if the patient is a legal adult. 
7
TITLE IV—FEDERAL RESEARCH 
8
SEC. 401. FEDERAL RESEARCH. 
9
(a) IN GENERAL.—Not later than 1 year after the 
10
date of enactment of this Act, the Secretary of Health and 
11
Human Services, in coordination with the Director of the 
12
National Institutes of Health and the heads of other rel-
13
evant Federal agencies, shall submit to the Caucus on 
14
International Narcotics Control, the Committee on the Ju-
15
diciary, and the Committee on Health, Education, Labor, 
16
and Pensions of the Senate and the Committee on Energy 
17
and Commerce and the Committee on the Judiciary of the 
18
House of Representatives a report on— 
19
(1) 
the 
potential 
therapeutic 
effects 
of 
20
cannabidiol or marijuana on serious medical condi-
21
tions, including intractable epilepsy; 
22
(2) the potential effects of marijuana, includ-
23
ing— 
24
21:54 Jul 21, 2022
H8454
23 
•HR 8454 IH
(A) the effect of increasing delta-9- 
1
tetrahydrocannabinol levels on the human body 
2
and developing adolescent brains; and 
3
(B) 
the 
effect 
of 
various 
delta-9- 
4
tetrahydrocannabinol levels on cognitive abili-
5
ties, such as those that are required to operate 
6
motor vehicles or other heavy equipment; and 
7
(3) the barriers associated with researching 
8
marijuana or cannabidiol in States that have legal-
9
ized the use of such substances, which shall in-
10
clude— 
11
(A) recommendations as to how such bar-
12
riers might be overcome, including whether pub-
13
lic-private partnerships or Federal-State re-
14
search partnerships may or should be imple-
15
mented to provide researchers with access to 
16
additional strains of marijuana and cannabidiol; 
17
and 
18
(B) recommendations as to what safe-
19
guards must be in place to verify— 
20
(i) the levels of tetrahydrocannabinol, 
21
cannabidiol, or other cannabinoids con-
22
tained in products obtained from such 
23
States is accurate; and 
24
21:54 Jul 21, 2022
H8454
24 
•HR 8454 IH
(ii) that such products do not contain 
1
harmful or toxic components. 
2
(b) ACTIVITIES.—To the extent practicable, the Sec-
3
retary of Health and Human Services, either directly or 
4
through awarding grants, contacts, or cooperative agree-
5
ments, shall expand and coordinate the activities of the 
6
National Institutes of Health and other relevant Federal 
7
agencies to better determine the effects of cannabidiol and 
8
marijuana, as outlined in the report submitted under para-
9
graphs (1) and (2) of subsection (a). 
10
Æ 
21:54 Jul 21, 2022
H8454
